Compare Inovio Pharmaceuticals Inc (INO) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Star Bulk Carriers Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while Star Bulk Carriers Corp trades at $27.81 (market cap $3.09B). The key difference: Star Bulk Carriers Corp is far larger — about 39.3× Inovio Pharmaceuticals Inc's market cap, and Star Bulk Carriers Corp pays a 6.79% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | SBLK | |
|---|---|---|
Market Cap | $78.55M | $3.09B |
Sector | Health | Industrials |
52-Week High | $2.87 | $29.15 |
52-Week Low | $0.66 | $16.79 |
Enterprise Value | $49.56M | $3.77B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Star Bulk Carriers (SBLK) trades at $27.81, down 2.15% on the day, but maintains a bullish technical outlook with strong support at $27. Fundamentally, the company reported robust Q2 2026 earnings of $1.21 per share, beating estimates, with net income surging to $144.9 million. Revenue growth accelerated to $1.2 billion in 2026, driving a net margin of 23.86%. Recent news highlights the termination of a vessel sale agreement with Diana Shipping, though operations remain unaffected.
The outlook for SBLK is positive, supported by strong profitability, a healthy balance sheet with a debt-to-asset ratio of 27.84%, and a shareholder-friendly dividend policy. Risks include exposure to volatile dry bulk shipping rates and competitive pressures. Analyst consensus is bullish with 58.34% buy ratings, indicating confidence in continued earnings momentum and valuation appeal at a P/E of 10.85.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
